Abstract:Abstract Background: Osteoporosis (OP) is a systemic metabolic bone disease that the bone resorption exceeds the bone formation,resulting in reduced bone mass, degeneration of the microstructure of bone tissue, and then increased bone fragility and fracture risk. Hyperoside (HP), as a natural product, can promote proliferation and differentiation of osteoblasts and presents a protective effect on ovariectomized (OVX) mice. However, the inhibitory effect of HP on osteoclasts (OCs) and the potential mechanism remains to be elucidated.Methods: In this study, RAW264.7 cells were used to generate OCs induced by RANKL, and HP was applied to the cell model. The effect of HP on OCs differentiation by TRAP-positive cell counting and TRAP activity test; Bone resorption assay and actin ring formation assay were used to verify the effect of HP on OCs function; The expression levels of osteoclast-specific genes and proteins were proved by RT-PCR and Western blotting.Results: HP significantly suppressed RANKL-induced OCs differentiation, function and the mRNAs expression levels of the osteoclast-related genes. Western Blotting results demonstrated that HP reduced the expression level of TNF receptor-associated factor 6 (TRAF6) and inhibited the p38 MAPK signing pathway by reducing the phosphorylation level of p38, which subsequently down-regulated the expression level of c-fos and NFATc1, ultimately, led to a decrease of the osteoclast-specific proteins CTSK and TRAP. In addition, TRAP-positive cell counting and TRAP activity test showed that HP could inhibit the differentiation of OCs; Bone resorption assay indicated that HP could restrain the OCs’ bone resorptive activity. Actin ring formation assay showed HP can cause the shrinkage of osteoclasts and disruption of actin ring structure.Conclusion: These results revealed that HP had an inhibitory effect on OCs by down-regulating TRAF6/p38 MAPK signaling pathway. Therefore, HP could be a promising natural compound for lytic bone diseases.

L‐tetrahydropalmatine Suppresses Osteoclastogenesis in Vivo and in Vitro Via Blocking RANK‐TRAF6 Interactions and Inhibiting NF‐κB and MAPK Pathways

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

Lycorine Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents Ovariectomy-Induced Osteoporosis and Titanium Particle-Induced Osteolysis in Vivo

Thiaplakortone B attenuates RANKL‐induced NF‐κB and MAPK signaling and dampens OVX‐induced bone loss in mice

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity

Tectoridin Inhibits Osteoclastogenesis and Bone Loss in a Murine Model of Ovariectomy-Induced Osteoporosis

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Astilbin Prevents Bone Loss in Ovariectomized Mice Through the Inhibition of RANKL‐induced Osteoclastogenesis

Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways

Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.

Low-intensity Pulsed Ultrasound Inhibits RANKL-induced Osteoclast Formation Via Modulating ERK-c-Fos-NFATc1 Signaling Cascades.

Tetrahydroberberine Prevents Ovariectomy-Induced Bone Loss by Inhibiting RANKL-Induced Osteoclastogenesis and Promoting Osteoclast Apoptosis

Matrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-induced Osteoclastogenesis

Zoledronic Acid Inhibits Osteoclast Differentiation And Function Through The Regulation Of Nf-Kappa B And Jnk Signalling Pathways

Retraction Note To: Matrine Derivate MASM Uncovers a Novel Function for Ribosomal Protein S5 in Osteoclastogenesis and Postmenopausal Osteoporosis

Hyperoside Suppresses Osteoclasts Differentiation and Function through Down-Regulating TRAF6/p38 MAPK Signaling Pathway

Tatarinan N Inhibits Osteoclast Differentiation Through Attenuating NF-κB, MAPKs and Ca2+-dependent Signaling.

Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways